Aberrant IDH3α expression promotes malignant tumor growth by inducing HIF-1-mediated metabolic reprogramming and angiogenesis

Oncogene

Volumn 34, Issue 36, 2015, Pages 4758-4766

  Zeng, L ^a,b   Morinibu, A ^a   Kobayashi, M ^a   Zhu, Y ^a,c   Wang, X ^a,b   Goto, Y ^a   Yeom, C J ^a   Zhao, T ^a,b   Hirota, K ^d   Shinomiya, K ^a   Itasaka, S ^a   Yoshimura, M ^a   Guo, G ^b   Hammond, E M ^e   Hiraoka, M ^a   Harada, H ^a,f  

^a KYOTO UNIVERSITY   (Japan)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^d KYOTO UNIVERSITY HOSPITAL   (Japan)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID; HYPOXIA INDUCIBLE FACTOR 1; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 3 ALPHA; UNCLASSIFIED DRUG; GLUCOSE; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC SCREENING; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HUMAN CELL; HYDROXYLATION; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOCITRATE DEHYDROGENASE; LUNG NEOPLASMS; MICE; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE PHOSPHORYLATION;

EID: 84940960811     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.411     Document Type: Article

References (31)

1. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
2. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29: 625-634.
3. Hirota K, Semenza GL. Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochem Biophys Res Commun 2005; 338: 610-616.
4. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468-472.
5. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001; 15: 2675-2686.
6. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basichelix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-5514.
7. Semenza GL. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 2009; 19: 12-16.
8. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012; 33: 207-214.
9. Harada H, Kizaka-Kondoh S, Hiraoka M. Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging 2005; 4: 182-193.
10. Shibata T, Akiyama N, Noda M, Sasai K, Hiraoka M. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. Int J Radiat Oncol Biol Phys 1998; 42: 913-916.
11. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-275.
12. Wakamatsu T, Tanaka T, Oda S, Nishi K, Harada H, Daijo H et al. The intravenous anesthetics barbiturates inhibit hypoxia-inducible factor 1 activation. Eur J Pharmacol 2009; 617: 17-22.
13. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995-4004.
14. Mizuno H, Kitada K, Nakai K, Sarai A. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics 2009; 2: 18.
15. Adler E, Euler HV, Gunther G, Plass M. isoCitric dehydrogenase and glutamic acid synthesis in animal tissues. Biochem J 1939; 33: 1028-1045.
16. McCarthy N. Metabolism: unmasking an oncometabolite. Nat Rev Cancer 2012; 12: 229.
17. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225-234.
18. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012; 483: 484-488.
19. Jiang BH, Zheng JZ, Leung SW, Roe R, Semenza GL. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem 1997; 272: 19253-19260.
20. Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 1987; 7: 2745-2752.
21. Harada H, Inoue M, Itasaka S, Hirota K, Morinibu A, Shinomiya K et al. Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun 2012; 3: 783.
22. Harada H, Itasaka S, Kizaka-Kondoh S, Shibuya K, Morinibu A, Shinomiya K et al. The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucoseand reoxygenation-dependent manner in irradiated tumors. J Biol Chem 2009; 284: 5332-5342.
23. Harada H, Itasaka S, Zhu Y, Zeng L, Xie X, Morinibu A et al. Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Br J Cancer 2009; 100: 747-757.
24. Harada H, Kizaka-Kondoh S, Itasaka S, Shibuya K, Morinibu A, Shinomiya K et al. The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun 2007; 360: 791-796.
25. Harada H, Kizaka-Kondoh S, Li G, Itasaka S, Shibuya K, Inoue M et al. Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene 2007; 26: 7508-7516.
26. Bao Y, Mukai K, Hishiki T, Kubo A, Ohmura M, Sugiura Y et al. Energy management by enhanced glycolysis in G1-phase in human colon cancer cells in vitro and in vivo. Mol Cancer Res 2013; 11: 973-985.
27. Bajad SU, Lu W, Kimball EH, Yuan J, Peterson C, Rabinowitz JD. Separation and quantitation of water soluble cellular metabolites by hydrophilic interaction chromatography-tandem mass spectrometry. J Chromatogr A 2006; 1125: 76-88.
28. Zeng L, Ou G, Itasaka S, Harada H, Xie X, Shibuya K et al. TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci 2008; 99: 2327-2335.
29. Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, Mitsudomi T et al. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol 2009; 27: 2793-2799.
30. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007; 13: 3207-3214.
31. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005; 7: R953-R964.